Haleon plc (NYSE:HLN) Stock Holdings Cut by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC cut its stake in shares of Haleon plc (NYSE:HLN) by 2.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,859,912 shares of the company’s stock after selling 45,111 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Haleon were worth $15,363,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Brown Advisory Inc. increased its position in Haleon by 14.1% during the fourth quarter. Brown Advisory Inc. now owns 41,427 shares of the company’s stock worth $341,000 after buying an additional 5,104 shares during the last quarter. Coldstream Capital Management Inc. boosted its holdings in shares of Haleon by 192.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 36,888 shares of the company’s stock worth $304,000 after acquiring an additional 24,270 shares in the last quarter. Trexquant Investment LP acquired a new position in Haleon during the 4th quarter worth $239,000. Assetmark Inc. raised its position in shares of Haleon by 25.5% during the 4th quarter. Assetmark Inc. now owns 14,405 shares of the company’s stock valued at $119,000 after acquiring an additional 2,929 shares during the last quarter. Finally, US Bancorp DE raised its position in shares of Haleon by 3.7% during the 4th quarter. US Bancorp DE now owns 774,972 shares of the company’s stock valued at $6,378,000 after acquiring an additional 27,572 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Price Performance

Haleon stock opened at $10.52 on Monday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $48.04 billion, a PE ratio of 35.07, a P/E/G ratio of 3.10 and a beta of 0.26. Haleon plc has a 12 month low of $7.70 and a 12 month high of $10.76. The stock has a 50-day moving average price of $9.76 and a two-hundred day moving average price of $8.88.

Haleon (NYSE:HLN) last released its earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The business had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same period in the prior year, the business earned $0.08 EPS. Analysts expect that Haleon plc will post 0.46 EPS for the current year.

Haleon Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were given a $0.0514 dividend. This represents a dividend yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon’s dividend payout ratio (DPR) is presently 33.33%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HLN. The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Berenberg Bank initiated coverage on Haleon in a research note on Tuesday, August 6th. They set a “buy” rating on the stock. Finally, Morgan Stanley boosted their target price on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.